Pediatric Patients (2 months up to 1 year)

- May be given in one or two doses on alternate days.

- The usual recommended dose for pediatric patients is 2 g per dose administered every 12 hours for 3 to 4 days for malaria prophylaxis.

- The maximum daily dose for pediatric patients should not exceed the recommended adult dose of 2 g per day.

DISEASE FORMS AND STRENGTHS

- For malaria prophylaxis, the recommended adult dose is 1 g per dose administered every 12 hours for 3 to 4 days.

- The usual recommended dose for pediatric patients is 2 g per dose administered every 12 hours for 3 to 4 days for malaria prophylaxis.

- The maximum daily dose for pediatric patients should not exceed the recommended adult dose of 2 g per day.

DISEASE FORMS AND STRENGTHS

- For malaria prophylaxis, the recommended adult dose is 1 g per dose administered every 12 hours for 3 to 4 days.

- The usual recommended dose for pediatric patients is 2 g per dose administered every 12 hours for 3 to 4 days for malaria prophylaxis.

- The maximum daily dose for pediatric patients should not exceed the recommended adult dose of 2 g per day.

CONTAINMENT

- Patients with advanced malignancies, especially in patients with existing infections, such as sepsis, may be treated with higher doses of cefepime to optimize lower concentrations and drug activity.

- Cefepime should not be used for infection in patients with severe neutropenia or who are neutropenic. (5.1)

- The use of high-dose cefepime for infection in patients with severe neutropenia or who are neutropenic should be discontinued soon after the neutrophil count recovers.

- The use of higher doses of cefepime for infection in patients with severe neutropenia or who are neutropenic should be discontinued soon after the neutrophil count recovers.

- The use of higher doses of cefepime for infection in patients with severe neutropenia or who are neutropenic should be discontinued soon after the neutrophil count recovers.

- The use of high-dose cefepime for infection in patients with severe neutropenia or who are neutropenic should be discontinued soon after the neutrophil count recovers.
WARMING PRESCRIPTIONS

DIRECTIONS FOR USE

6. ADVERSE REACTIONS

6.1 Clinical Trial Experience

6.2 Postmarketing Experience

6.3 Eczematoid Contact Dermatitis

6.4 Infectious Complications

6.5 Specific Pathogens

6.6 Other Effects

6.7 Immunological Effects

7. WARNINGS/ PRECAUTIONS

7.1 Liver Function Tests

7.2 Porcine Kidney Derived Enzymes

7.3 Gastrointestinal Overgrowth

7.4 Cholesterol, Triglyceride, and Blood Lipoprotein Levels

7.5 Blood Glucose Levels

7.6 Carcinogenesis, Mutagenesis, Impairment of Fertility

7.7 Pregnancy

7.8 Nursing Mothers

7.9 Pediatric Use

7.10 Geriatric Use

8. ADVERSE REACTIONS

8.1 General

8.2 Cardiovascular

8.3 Nervous System

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Infectious Complications

8.8 Other Effects

9. DOSAGE AND ADMINISTRATION

10. NONCLINICAL PHARMACOLOGY

11. DESCRIPTION

12. PHARMACOKINETICS

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13. CLINICAL PHARMACOLOGY

14. CLINICAL TRIALS

15. ADVERSE REACTIONS

16. HOW SUPPLIED/STORAGE AND HANDLING

17. PATIENT COUNSELING INFORMATION

18. NURSING MOTHERS

19. MANUFACTURER

20. PATIENT醫 DATA

21. PATIENT MEDICATION GUIDE